NCT05412277View on ClinicalTrials.gov

VIA Disc Nucleus Pulposus Older Patients Pilot

NAActive, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

October 17, 2022

Primary Completion Date

August 30, 2024

Study Completion Date

December 31, 2024

Conditions
Degenerative Disc DiseaseLow Back PainDisc Degeneration
Interventions
OTHER

VIA Disc Nucleus Pulposus Allograft

A single dose, intradiscal injection of 100mg of VIA Disc NP mixed with 2ml sterile saline administered to the affected 1 to 3 levels, L1-S1.

Trial Locations (5)

27103

Center for Clinical Research, Winston-Salem

30263

Southern Pain and Spine Associates, Newnan

33614

Florida Spine & Pain Specialists, Tampa

70458

Paradigm Spine Care & Interventional Pain, Slidell

75701

Precision Spine Care, Tyler

All Listed Sponsors
lead

VIVEX Biologics, Inc.

INDUSTRY